echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > One picture to understand the similarities and differences between different "biological agents"

    One picture to understand the similarities and differences between different "biological agents"

    • Last Update: 2022-01-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Biologics are not good or bad, only suitable and unsuitable, so it is difficult to distinguish between "good" and "bad
    .
    "
    However, the "targets" targeted by biologics are different, so they can be classified accordingly, reflecting some of their characteristics

    .

    At present, the most commonly used biological agents in clinical can be divided into two categories, namely interleukin-17A inhibitors and tumor necrosis factor antagonists.
    These two categories of biological agents also include several small categories.
    For details, please refer to the following table

    .

    Biologics are not good or bad, only suitable and unsuitable, so it is difficult to distinguish between "good" and "bad
    .
    "
    However, the "targets" targeted by biologics are different, so they can be classified accordingly, reflecting some of their characteristics

    .

    At present, the most commonly used biological agents in clinical can be divided into two categories, namely interleukin-17A inhibitors and tumor necrosis factor antagonists.
    These two categories of biological agents also include several small categories.
    For details, please refer to the following table

    .

    At present, the most commonly used biological agents in clinical can be divided into two categories, namely interleukin-17A inhibitors and tumor necrosis factor antagonists.
    These two categories of biological agents also include several small categories.
    For details, please refer to the following table

     

    Which patients can use biologics?

    1.
    The disease is in the acute stage and critical stage: ① Hip joint involvement, peripheral joint involvement (Achilles tendinitis, iritis, etc.
    ), etc.
    , will directly affect future walking, and the disability rate is extremely high; ② The inflammatory index is abnormally high For patients with ankylosis, biological agents can be selected for treatment, and the onset is fast;

    2.
    Inadequate traditional drug treatment: use at least two different types of non-steroidal anti-inflammatory drugs for more than 4 weeks without response, and can be replaced by biological agents to achieve the purpose of relieving the disease and protecting joint/spine function;

    3.
    Side effects caused by the use of traditional drugs: Traditional oral drugs often have some adverse reactions: such as liver function damage, leukopenia, affecting menstruation, pulmonary fibrosis, etc.
    Because of such side effects, patients who cannot use traditional drugs can be changed to biological Preparation treatment

    .

    Which types of ankylosing spondylitis patients need combination therapy?

    If the patient has had difficulty in hunchback, squatting, bending over, or even paralyzed in bed, at this time, no matter which biological agent is used, it will not help, because the deep inflammation of the patient's joint cavity has accumulated, and adhesions and fusions have been formed.
    Preparation treatment can only control the superficial inflammation of the joints, and cannot effectively reduce inflammation in deep layers, release joint adhesions, repair bone, etc.
    , and cannot truly block the formation of osteophytes.
    Therefore, it needs to be combined with local fixed-point minimally invasive treatment

    .

    Which types of ankylosing spondylitis patients are not suitable for biologics

    ① There is an active infection

    Infect

    ② Those with combined or hepatitis B infection history without standard treatment or active

    ③ History of Pneumocystis carinii pneumonia

    ④ Combined with moderate to severe congestive heart failure

    ⑤ Patients with malignant tumor

    ⑥ Demyelinating lesions of the nervous system

    ⑦Allergies

    ⑧It is not recommended to use during pregnancy, pregnancy and breastfeeding

    Be wary of side effects with biologics!

    ① Infection: such as respiratory tract infection, urinary tract infection, tuberculosis, pneumonia, etc.
    ;

    ②Tumor: Excessive immunosuppression increases the risk of tumorigenesis;

    immunity

    ③ Injection site reactions: redness, swelling, rash,
    etc.

    Pre- and post-use screening programs for biologics

    screening

    In order to ensure the safety of biological preparations, blood routine tests, erythrocyte sedimentation rate, CPR, liver and kidney function, viral hepatitis series, TSPOT, chest X-ray and other tests are required before use to exclude tumors, active infections, tuberculosis, hepatitis,
    etc.
    After using biological agents, it is also necessary to regularly go to the hospital to review the erythrocyte sedimentation rate, C-reactive protein, blood routine, urine routine, etc.
    , and be alert to the side effects after use

    .

    How long to stop using biologics

    The use of biological agents generally does not have a course of treatment, but some doctors will give patients a 3-6 month course of treatment because of the cost and risk of side effects, so as to control the acute stage disease into a stable stage, but it does not mean that it will not be stopped after stopping.
    relapse

    .
    Because the immunosuppression of biological agents can control inflammation in the short term, but some patients have inflammation in the deep joint cavity, it is difficult to remove it, and the residual inflammation will cause the recurrence of symptoms.
    At the same time, immunosuppression does not mean immune regulation.
    The imbalance leads to new inflammatory proliferations, as well as the risk of infection and tumors

    .

    In summary:

    The selection and applicability of biological agents should be determined according to multiple factors such as the patient's condition, physical condition, and economic conditions.
    Through detailed communication with doctors, a more suitable treatment plan should be selected

    .



    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.